A Phase 2 Randomized Open Label Study of the Safety and

  • Ustun, Celalettin (PI)

Project: Research project

Project Details

Description

A Phase 2 Randomized Open Label Study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
StatusFinished
Effective start/end date2/1/121/31/17

Funding

  • Astellas Pharma US, Inc.

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.